

April 1, 2008

Archimica expands cryogenic capacity for boronic acid production

Sulzbach, Germany. Archimica has decided to invest significantly in the increase of cryogenic production capacity at its sites in Frankfurt and Bon Encontre based on the increasing demand of pharmaceutical companies for organometallic and other low-temperature products.

With a completely new cryogenic 3000 L production train coming on stream in the second half of 2008 at its Bon Encontre site and further throughput increase investments at its Frankfurt site, Archimica will be able to offer low-temperature chemistry at all scales from kilolab via pilot plant up to large-scale commercial production at all of its entities in Italy, US, France, UK and Germany.

“Based on our experience in the development and upscaling of more than 100 boronic acids in the past decade, the successful commercial scale production of several 10 tons per year of difficult aryl boronic acids, and our unique technology basis, we want to grow further in this area.” said **Archimica’s Managing Director for New Business Development, Andreas Meudt**. *“We look forward to continuing the fast and reliable development of increasingly more complex products with our customers.”*, Meudt added.

The Archimica team has in total almost two decades of experience in the synthesis and downstream chemistry of challenging boronic acids and other organometallic products for a variety of customers. More than 30 patents have been filed in this area over the past years.

These activities are part of the strategic focus of Archimica on strong technological differentiation and entering new projects preferably in clinical phases II and III, in very close cooperation with its customers. Based on this focus, the global Business Unit in which these activities are organized within Archimica has experienced very strong growth over the past decade.

Archimica – Strong. Steady. Focused on Pharmaceuticals.

Archimica is a privately held pharmaceutical fine chemicals company. Archimica combines world-scale chemical manufacturing experience with a history of pharmaceutical commercialization that stretches back over 40 years. With seven production sites in Italy, France, Germany, UK and the US and 2006 sales of 200 Mio US\$, the company is particularly focused on custom synthesis of high-tech building blocks, intermediates and APIs in close cooperation with its clients. Archimica’s core technologies are cryogenic reactions especially for boronic acids (8 full-scale – 100 °C production lines up to 12.000 L), Pd-catalyzed chemistries for biaryls and C,X-couplings, hydrogenations up to 80 bar, phosgenation with triphosgene, heterocyclic products, enzymatic chemistries, nitrations and aseptic filtration for bulk steriles.